SeaStar Medical Holding Corporation — FY2023 Form 10-K
Reporting period: Year ended December 31, 2023. Filed April 16, 2024. The company is a clinical-stage medical-device developer with no commercial product revenue. Its Selective Cytopheretic Device (SCD) is designed to modulate hyperinflammation and initially targets acute kidney injury (AKI) in patients receiving continuous renal replacement therapy (CRRT).
Financial performance and condition
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022, restated |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.973 million | $2.503 million |
| General and administrative expense | $8.237 million | $6.916 million |
| Operating loss | $14.210 million | $11.609 million |
| Net loss | $26.232 million | $12.190 million |
| Net loss per share, basic and diluted | $1.21 | $1.48 |
| Cash used in operating activities | $10.285 million | $7.794 million |
| Cash and total assets | $0.176 million; $3.513 million | $0.047 million; $3.038 million |
| Debt carrying values | $4.708 million notes payable; $4.373 million convertible notes | $8.830 million notes payable; no convertible notes outstanding at year-end |
Operating expenses rose 22%; R&D increased 139%, primarily reflecting clinical-trial and personnel costs. Net loss more than doubled, largely due to noncash fair-value changes and a $4.949 million loss on extinguishment of convertible notes, as well as higher operating costs. Interest expense was $1.081 million. There was no meaningful sales base from which to assess gross or operating margins.
Financing activities provided $10.414 million in 2023, versus $7.331 million in 2022. The company ended 2023 with $13.046 million of current liabilities against $2.308 million of current assets. The balance-sheet figures imply a $10.738 million working-capital deficit; elsewhere, the filing cites a $4.2 million deficit, so the discrepancy should be reconciled. The auditor and management both report substantial doubt about the company’s ability to continue as a going concern for at least 12 months after issuance absent additional financing.
Material changes, developments and outlook
- Restatement: The company restated its 2022 annual financial statements and its first three 2023 quarterly statements after identifying material errors. The 2022 net loss changed from $23.013 million as previously reported to $12.190 million as restated. Restatement matters included accounting for warrants and embedded features of forward purchase agreements, and reclassifications. FY2023 annual results were not restated.
- Regulatory progress: After year-end, on February 22, 2024, the FDA granted an HDE for the pediatric SCD for children weighing at least 10 kg with AKI and sepsis or a septic condition receiving CRRT in a hospital ICU. HDE sales and distribution restrictions apply; the filing does not state the specific annual distribution limit.
- Adult trial: The 200-subject randomized pivotal SCD-006 adult AKI trial began enrollment in 2023. The filing describes interim results in late 2024 and topline results/PMA submission in early 2026, but other passages give different timelines. There is no assurance of timely enrollment, positive results, or FDA approval.
- Funding and dilution: The $100 million Tumim equity line was terminated by mutual agreement on February 15, 2024; the company had received $1.9 million under it through February 15. A January 2024 offering issued common shares and pre-funded warrants, alongside additional warrants; the excerpt does not provide a clear amount of net cash proceeds. Common shares outstanding increased from 47.6 million at year-end to 75.4 million as of March 31, 2024.
- Other financing developments: Investor D convertible notes and warrants generated substantial dilution and fair-value expense. The filing reports subsequent note conversions into shares and warrant exercises. The LMFAO note was paid in full in January 2024. The company had $4.179 million of convertible notes classified as current and $0.194 million as noncurrent at year-end.
- Listing risk: The company regained compliance with Nasdaq’s market-value requirement in February 2024, but received a temporary exception on the $1 minimum-bid-price requirement through June 24, 2024, subject to milestones; a reverse stock split was among the stated options.
- Management and controls: Disclosure controls were ineffective at year-end, and the company identified material weaknesses involving segregation of duties and accounting expertise for complex instruments. Management did not provide an ICFR effectiveness assessment, citing unreasonable effort or expense. The filing says it added an experienced controller and CFO and plans further remediation.
- Commercial and execution risks: The company relies on third parties for manufacturing and development and identifies a single-source filter supplier for the pediatric indication. Reimbursement, hospital adoption, manufacturing scale-up, clinical outcomes, and further financing remain uncertain. The company reported 12 full-time employees at year-end.
Most important facts for investors to verify
- Cash runway, near-term financing needs, and whether subsequent financings provide adequate funds; reconcile the filing’s conflicting working-capital figures.
- The exact HDE label, annual distribution limit, launch status, distributor terms, and reimbursement pathway.
- Adult pivotal-trial enrollment, interim and final result timing, and the differing PMA timelines stated in the filing.
- All outstanding debt, conversion terms, warrants, and potential share dilution; confirm current share count and remaining note obligations.
- Progress in remediating the material weaknesses and preventing further reporting errors or restatements.
- Nasdaq minimum-bid-price compliance status and any reverse-split action.